Labcorp (LH) Q3 2026 earnings review
Labcorp raises its outlook as clinical-trial orders grow again
Labcorp, the medical testing and drug-trial laboratory group, accelerated its underlying sales growth and restarted its clinical-trial order book. Revenue rose 7%, while profit per share excluding one-offs climbed 15% on cost savings and earlier share buybacks. Chief executive Adam Schechter raised the full-year sales and profit outlook for a third straight quarter, leaving fourth-quarter revenue on track to grow about 7% by our math.
| Sales from businesses owned a year ago | +5.5% from a year ago (total revenue $3.81B, +6.9%) |
|---|---|
| Profit per share, excluding one-offs | $4.78 +14.5% from a year ago (reported EPS $3.22, +3.3%) |
| Biopharma contracted backlog | $8.92B +3.9% from a year ago (trailing book-to-bill 1.10) |
| Full-year outlook | Raised middle of the range: 6.3% sales growth and $18.50 EPS |
⚖️ Verdict: 🟢 Bullish
The story got better because the three main worries from the first half all improved at once. Biopharma backlog broke out of a four-quarter stall as trailing orders reached 1.10 times sales, specialty testing lifted Diagnostics prices and mix back above 3%, and a 47% jump in free cash flow removed the pressure on fourth-quarter cash generation. One caution: reported operating margin slipped as restructuring, deal integration, and system expenses climbed.
The question now is how much of Labcorp's profit expansion reaches the bottom line as it absorbs three more acquisitions signed after quarter-end. Supporters see a repeatable formula of buying lab volume and cutting operating costs, while skeptics point to $168 million of quarterly one-off charges that kept reported net income nearly unchanged. Fourth-quarter restructuring charges and the 2027 outlook will show whether those deal costs start to come down.
🐂 Bull Case
Biopharma Order Book Broke Out of Its Stall
Biopharma Laboratory Services, the division that runs clinical trials and drug testing for pharmaceutical companies, had a flat order book around $8.7 billion for four straight quarters. That plateau ended this quarter, and the company raised the division's full-year sales outlook by nearly two percentage points.
- Contracted backlog: $8.92 billion, up 3.9% from a year ago and up $190 million from last quarter
- Trailing twelve-month book-to-bill (orders won divided by sales): 1.10, up from 1.03 last quarter
- Trailing twelve-month net orders: $3.59 billion, up from $3.32 billion in Q2
- Backlog expected to turn into revenue over the next 12 months: $2.82 billion, up from $2.75 billion
The jump in trailing orders indicates roughly $980 million of new business in the third quarter by our math, because a weak year-ago quarter dropped out of the twelve-month window. Combined with an 8.5% revenue increase this quarter and the higher full-year plan, both the quarter and the outlook confirm that drug-development demand is growing again.
What to watch: fourth-quarter backlog and book-to-bill when full-year results arrive in February. Holding the trailing ratio near 1.10 against a tougher fourth-quarter comparison would support high-single-digit biopharma growth in 2027.
Specialty Tests Lifted Routine Lab Prices
Diagnostics Laboratories, Labcorp's main network of patient testing centers, relies on complex specialty tests to raise the average revenue collected per patient order. Chief executive Adam Schechter said the group widened its lead in specialty testing by launching new assays for advanced melanoma, Alzheimer's disease, and hepatitis D.
Underlying prices and product mix in Diagnostics rose 3.1% from a year ago, rebounding from 1.8% in both the first and second quarters. Combined with a 1.3% rise in underlying test volume, sales from businesses owned a year ago grew 4.4% even against last year's 6.3% comparison, and the company raised its full-year Diagnostics sales plan.
What to watch: fourth-quarter underlying prices and mix in Diagnostics. A reading near 3% when volume comparisons ease in the fourth quarter would push underlying division growth back toward 5%.
Cost Savings Lifted Margins for a Sixth Quarter
"Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance," Schechter said. Operating margin excluding one-offs rose 0.6 percentage points from a year ago to 15.0%, marking a sixth consecutive quarter of improvement as the company upgraded its Global Trial Connect portal.
By our math, the cost of performing tests fell 0.3 percentage points of revenue to 70.9%, and overhead and selling expenses excluding one-offs fell 0.2 points to 14.1%. Biopharma margin rose 1.8 points to 18.3% on "organic growth and operating efficiencies from the strategic actions taken in Early Development", its early-stage drug testing unit that grew 0.4% after shrinking in Q2.
What to watch: Early Development revenue growth in the fourth quarter, when it compares against a 13.5% drop a year ago. A return to mid-single-digit growth would show the site closures are complete and sustain Biopharma margins above 17%.
Working Capital Rebound Eased the Cash Hurdle
Entering the quarter, Labcorp's unchanged full-year free cash flow plan of $1.24 billion to $1.36 billion looked stretched because first-half cash flow was down 12% from a year earlier. In the third quarter, free cash flow rose 47% from a year ago to $412.2 million as the company managed accounts payable and inventory more tightly.
Nine-month free cash flow reached $796.6 million, up 11.3% from a year ago despite $93.6 million more in capital spending. By our math, the middle of the full-year outlook now leaves $503.4 million for the fourth quarter, just 2.7% above last year's fourth quarter, fading the risk of a cash shortfall.
What to watch: fourth-quarter operating cash flow and capital spending. Collecting recent receivables will determine whether full-year free cash flow finishes near the $1.30 billion middle of the range.
🐻 Bear Case
Deal and Restructuring Costs Cut Reported Margin
Labcorp uses hospital and regional lab acquisitions to add testing volume, and supporters view its steady deal pipeline as a reliable growth engine. Schechter highlighted "expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses", noting four deals that should be "accretive to adjusted EPS in year one and return cost of capital by year three".
- Reported operating margin: 10.6%, down 0.6 percentage points from 11.1% a year ago
- Operating profit adjustments: $167.9 million, up 44% from $116.7 million a year ago
- LaunchPad system and consulting charges: $28.6 million, more than double last year's $13.7 million
- Acquisition, disposition, and restructuring charges: $38.9 million, up from $16.7 million a year ago
- Loss from minority stake in European lab group SYNLAB: $10.9 million, more than double last year's $5.0 million
While management emphasized expanding margins excluding one-offs, total selling and administrative expenses on the income statement rose 0.5 percentage points of revenue, and intangible amortization rose 13% to $78.7 million. Because Labcorp spent $683.4 million on acquisitions over nine months and just signed agreements for BioReference assets, Myriad Genetics' prenatal business, and Millennium Health, these integration and amortization costs are recurring expenses that kept reported net profit nearly unchanged at $262.8 million.
What to watch: acquisition and LaunchPad charges in the fourth-quarter reconciliation table. If quarterly operating adjustments stay near $170 million as the three new deals close, reported profit will keep trailing the company's headline earnings.
Risks This Quarter Didn't Answer
Labcorp's third-quarter earnings release announced new tests—including FDA approval for its PGDx elio tissue complete "companion diagnostic to help identify patients with advanced melanoma", the Marker genetic panel on Labcorp OnDemand, and an at-home HPV screening partnership with Waters Corporation—but gave no numbers on five standing concerns.
- Medicare 2027 rate cuts (PAMA): no update in the release on the planned $100 million revenue and profit hit or the September Analyst Day mitigation plan.
- Medicaid and ACA coverage losses: no third-quarter figure for the 0.2 to 0.3 percentage point volume drag discussed last quarter; the earnings call and 10-Q filing will be the first places to check.
- Specialty and consumer revenue size: OnDemand now offers over 140 tests, but management still did not disclose revenue for specialty, neurology, or consumer testing.
- Ravgen patent appeal: no update in the release on the appeal of the $372 million patent verdict; the 10-Q legal footnote will show its status.
- At-home self-collection impact: no data on whether at-home tests are pulling routine visits away from Labcorp's physical patient service centers.
💲 Other KPIs
Accounts receivable—money owed by patients, insurers, and drug companies for completed lab work—rose $70.5 million in the third quarter and is up 14.7% since December 2025. That is more than double the 6.2% nine-month revenue growth rate, absorbing $317.3 million of operating cash flow so far this year.
Spending on property and lab equipment jumped 42.1% from a year ago to reach 4.0% of revenue, up from 3.5% in the first half. The diagnostic group is building a 500,000-square-foot central laboratory facility in Indiana, which lifted nine-month capital spending by 30.1% to $404.2 million.
Weighted-average diluted shares fell 2.5% from a year ago and 0.5% from the second quarter, boosting per-share profit growth by about 2.5 percentage points. After spending $451.8 million on share buybacks in the first half, the company bought back no stock in the third quarter and kept $1.4 billion of authorization.
🔮 Guidance
Raised. The middle of the full-year sales range moved up $64.5 million to $14,833 million, or 6.3% growth. By our math, that leaves $3,754 million for the fourth quarter, or 6.8% growth from a year ago against Q3's 6.9%. This is the third raise this year, and each step has grown larger: +20, +30, and +45 basis points.
Raised. Labcorp lifted the middle of the Diagnostics target by $22 million to $11,513 million, or 5.9% growth for the year. By our math, that points to $2,901 million in the fourth quarter, up 6.3% from a year ago as the division laps an easier 1.1% underlying volume quarter from late 2025.
Raised. The clinical-trial unit's target rose $58.5 million at the middle of the range to $3,343 million, or 7.9% growth, despite currency help trimming from 1.5% to 1.3%. By our math, the outlook implies $860 million of fourth-quarter revenue, or 8.4% growth, matching Q3's 8.5% pace as Early Development laps a 13.5% drop.
Raised. Profit per share excluding one-offs moved up $0.18 at the middle of the range to $18.50, or 12.5% growth for the year. By our math, that leaves $4.48 for the fourth quarter, up 10.1% from a year ago versus 14.5% in Q3. It is the third raise of 2026: +$0.13, +$0.30, and +$0.18.
Unchanged. The full-year cash plan stays at $1.30 billion in the middle of the range, or 7.8% growth over 2025. After generating $796.6 million in the first nine months, the company needs $503.4 million in the fourth quarter by our math, a 2.7% increase over last year's fourth quarter.
❓ Key Questions
What will the three newly signed acquisitions cost?
Labcorp announced agreements to buy clinical testing assets from BioReference Health, Myriad Genetics' prenatal business, and Millennium Health, while pausing share buybacks in Q3. Disclosing the purchase prices and expected revenue will show how much cash they require and how much growth they add in 2027.
Why did operating adjustments and SYNLAB losses jump?
Operating adjustments excluded from headline profit rose 44% to $167.9 million, led by $28.6 million in LaunchPad system costs, while losses on the minority stake in SYNLAB more than doubled to $10.9 million. Investors need to know when these charges will peak.
What is the 2027 plan if Medicare cuts lab rates?
Management previously sized the potential January 2027 Medicare rate reduction (PAMA) at $100 million of revenue and profit, and pointed to its September Analyst Day for details. With the third-quarter release silent on the topic, what offsets are now in place?
Why are customer receivables growing twice as fast as sales?
Accounts receivable have climbed 14.7% since the end of 2025 to $2.41 billion, compared with 6.2% nine-month revenue growth. Is the build coming from newly acquired hospital outreach labs, or are insurers and patients taking longer to pay?